This Article Abstract Full Text (PDF) All Versions of this Article: 109/3/351    most recent 01.CIR.0000109493.05849.14v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nagaya, N. Articles by Kangawa, K. Search for Related Content PubMed PubMed Citation Articles by Nagaya, N. Articles by Kangawa, K. Related Collections Pulmonary circulation and disease

(Circulation. 2004;109:351-356.)
© 2004 American Heart Association, Inc.

Clinical Investigation and Reports

Effects of Adrenomedullin Inhalation on Hemodynamics and Exercise Capacity in Patients With Idiopathic Pulmonary Arterial Hypertension

Noritoshi Nagaya, MD; Shingo Kyotani, MD; Masaaki Uematsu, MD; Kazuyuki Ueno, PhD; Hideo Oya, MD; Norifumi Nakanishi, MD; Mikiyasu Shirai, MD; Hidezo Mori, MD; Kunio Miyatake, MD; Kenji Kangawa, PhD

From the Department of Internal Medicine, National Cardiovascular Center, Osaka (N. Nagaya, S.K., H.O., N. Nakanishi, K.M.); the Cardiovascular Division, Kansai Rosai Hospital, Hyogo (M.U.); the Department of Pharmacy, National Cardiovascular Center, Osaka (K.U.); the Department of Cardiac Physiology, National Cardiovascular Center Research Institute, Osaka (M.S., H.M.); and the Department of Biochemistry, National Cardiovascular Center Research Institute, Osaka (K.K.), Japan.

Correspondence to Noritoshi Nagaya, MD, Department of Internal Medicine, National Cardiovascular Center, 5-7-1 Fujishirodai, Suita, Osaka 565-8565, Japan. E-mail nagayann{at}hsp.ncvc.go.jp

Received February 3, 2003; de novo received July 28, 2003; revision received October 15, 2003; accepted October 19, 2003.

	Abstract

Top Abstract Introduction Methods Results Discussion Conclusions References

 
Background— Adrenomedullin (AM) is a potent pulmonary vasodilator peptide. However, whether intratracheal delivery of aerosolized AM has beneficial effects in patients with idiopathic pulmonary arterial hypertension remains unknown. Accordingly, we investigated the effects of AM inhalation on pulmonary hemodynamics and exercise capacity in patients with idiopathic pulmonary arterial hypertension.

Methods and Results— Acute hemodynamic responses to inhalation of aerosolized AM (10 µg/kg body wt) were examined in 11 patients with idiopathic pulmonary arterial hypertension during cardiac catheterization. Cardiopulmonary exercise testing was performed immediately after inhalation of aerosolized AM or placebo. The work rate was increased by 15 W/min until the symptom-limited maximum, with breath-by-breath gas analysis. Inhalation of AM produced a 13% decrease in mean pulmonary arterial pressure (54±3 to 47±3 mm Hg, P<0.05) and a 22% decrease in pulmonary vascular resistance (12.6±1.5 to 9.8±1.3 Wood units, P<0.05). However, neither systemic arterial pressure nor heart rate was altered. Inhalation of AM significantly increased peak oxygen consumption during exercise (peak O₂, 14.6±0.6 to 15.7±0.6 mL · kg^-1 · min^-1, P<0.05) and the ratio of change in oxygen uptake to that in work rate (O₂/W ratio, 6.3±0.4 to 7.0±0.5 mL · min^-1 · W^-1, P<0.05). These parameters remained unchanged during placebo inhalation.

Conclusions— Inhalation of AM may have beneficial effects on pulmonary hemodynamics and exercise capacity in patients with idiopathic pulmonary arterial hypertension.

Key Words: peptides • hypertension, pulmonary • respiration • exercise • hemodynamics

	Introduction

Top Abstract Introduction Methods Results Discussion Conclusions References

 
Idiopathic pulmonary arterial hypertension is a rare but life-threatening disease characterized by progressive pulmonary hypertension, ultimately producing right heart failure and death.^1,2 Although a variety of vasodilators have been proposed as potential therapy for this disease over the past 30 years,^3–7 some patients ultimately require heart-lung or lung transplantation.^8,9 Thus, a novel therapeutic strategy is desirable.

Adrenomedullin (AM) is a potent, long-lasting vasodilator peptide that was originally isolated from human pheochromocytoma.¹⁰ Immunoreactive AM has subsequently been detected in plasma and a variety of tissues, including blood vessels and lungs.^11,12 It has been reported that there are abundant binding sites for AM in the lungs.¹³ We have shown that the plasma AM level increases in proportion to the severity of pulmonary hypertension and that circulating AM is partially metabolized in the lungs.^14,15 Interestingly, AM has been shown to inhibit the migration and proliferation of vascular smooth muscle cells.^16,17 These findings suggest that AM plays an important role in the regulation of pulmonary vascular tone and vascular remodeling. In fact, we have shown that short-term intravenous infusion of AM significantly decreases pulmonary vascular resistance in patients with congestive heart failure¹⁸ or pulmonary arterial hypertension.¹⁹ Unfortunately, however, intravenously administered AM induced systemic hypotension in such patients because of nonselective vasodilation in the pulmonary and systemic vascular beds.

More recently, inhalation of aerosolized prostacyclin and its analogue iloprost has been shown to cause pulmonary vasodilation without systemic hypotension in patients with idiopathic pulmonary arterial hypertension.^20,21 In addition, inhalant application of vasodilators does not impair gas exchange because the ventilation-matched deposition of drug in the alveoli causes pulmonary vasodilation matched to ventilated areas.²⁰ In clinical settings, inhalation therapy may be more simple, noninvasive, and comfortable than continuous intravenous infusion therapy. Thus, the purpose of the present study was to investigate the effects of AM inhalation on hemodynamics and exercise capacity in patients with idiopathic pulmonary arterial hypertension.

	Methods

Top Abstract Introduction Methods Results Discussion Conclusions References

 
Study Subjects
Eleven patients with idiopathic pulmonary arterial hypertension (9 women and 2 men; age, 39±3 years) were included in this study. Idiopathic pulmonary arterial hypertension was defined as pulmonary hypertension unexplained by any secondary cause, on the basis of the criteria of the National Institutes of Health registry.¹ Ten patients were classified as New York Heart Association (NYHA) functional class III and 1 as class IV (Table 1). Two of the 11 patients (18%) were acute responders who showed a significant decrease in mean pulmonary arterial pressure of 20% with a decrease in mean pulmonary arterial pressure to <35 mm Hg and no change or an increase in cardiac index during short-term infusion of epoprostenol. Long-term medication, including anticoagulant agents, digitalis, and diuretics, was kept constant. Vasodilator agents, such as oral prostacyclin analogue and calcium antagonists, were stopped 12 hours before the study procedure was begun. The ethics committee of the National Cardiovascular Center approved the study, and all patients gave written informed consent.

View this table: [in this window] [in a new window]   TABLE 1. Baseline Characteristics of Patients With Idiopathic Pulmonary Arterial Hypertension

Preparation of Human AM
Human AM was dissolved in saline with 4% D-mannitol and sterilized by passage through a 0.22-µm filter (Millipore Co). At the time of dispensing, randomly selected vials were submitted for sterility and pyrogen testing. The chemical nature and content of the human AM in vials were verified by high-performance liquid chromatography and radioimmunoassay. All vials were stored frozen at -80°C from the time of dispensing until the time of preparation for administration.

Hemodynamic Studies
Acute hemodynamic responses to AM inhalation were assessed in all patients while they were in a stable condition during hospitalization. Hemodynamic variables, including pulmonary arterial pressure, right atrial pressure, pulmonary capillary wedge pressure, and cardiac output (in triplicate), were determined with a thermodilution catheter (TOO21H-7.5F, Baxter Co).²² A 22-gauge cannula was inserted into a radial artery for hemodynamic measurements and blood sampling. After an equilibration period of 30 minutes, baseline hemodynamics were measured. Then, AM (10 µg/kg body wt) was inhaled as an aerosol with a jet nebulizer (Porta-Nebu, MEDIC-AID) for 15 minutes, which resulted in a cumulative dose of 400 to 600 µg AM. Hemodynamic parameters were measured at 15-minute intervals starting 15 minutes before AM inhalation until 60 minutes after inhalation. Blood samples for AM measurement were taken at 15-minute intervals from 15 minutes before inhalation until 60 minutes after the end of inhalation.

Cardiopulmonary Exercise Testing
The effects of AM inhalation on exercise capacity were examined in 10 of 11 patients; 1 patient with NYHA class IV underwent the 6-minute walk test according to decision of attending physicians. Cardiopulmonary exercise testing was performed immediately after inhalation of aerosolized AM (10 µg/kg body wt) or saline in a double-blind, randomized, crossover design. This study was performed on 2 separate days, 1 week apart. The first cardiopulmonary exercise testing was performed within 10 days after the cardiac catheterization. The patients performed exercise seated on a cycle ergometer. They first pedaled at 55 rpm without any added load for 1 minute. The work rate was then increased by 15 W/min up to the symptom-limited maximum. Breath-by-breath gas analysis was performed with an AE280 (Minato Medical Science) connected to a personal computer running analyzing software.²³ The ratio of change in oxygen uptake to that in work rate (O₂/W ratio) was calculated as the slope of oxygen consumption per unit workload from 1 minute after the start of load addition until 85% maximal O₂. Exercise capacity was evaluated by peak oxygen consumption (peak O₂), which was defined as the value of averaged data during the final 15 seconds of exercise. Ventilatory efficiency during exercise was represented by the E-CO₂ slope, which was determined as the linear regression slope of E and CO₂ from the start of exercise until the RC point (the time until which ventilation is stimulated by CO₂ output and end-tidal CO₂ tension begins to decrease).

Measurement of Plasma AM, cAMP, and cGMP
Blood samples were immediately transferred into chilled glass tubes containing disodium EDTA (1 mg/mL) and aprotinin (500 U/mL) and centrifuged immediately at 4°C, and the plasma was frozen and stored at -80°C until assayed. Plasma AM level was measured by a specific immunoradiometric assay kit (Shionogi Pharmaceutical Co Ltd).²⁴ Plasma cAMP and cGMP were determined with radioimmunoassay kits (cAMP assay kit, cGMP assay kit, Yamasa Shoyu).¹⁸

Statistical Analysis
All data were expressed as mean±SEM unless otherwise indicated. Changes in hemodynamic and hormonal parameters by AM inhalation were analyzed by 1-way ANOVA for repeated measures, followed by Newman-Keuls test. Comparisons of exercise parameters between the 2 groups were analyzed with paired Student’s t test. A probability value of P<0.05 was considered statistically significant.

	Results

Top Abstract Introduction Methods Results Discussion Conclusions References

 
All patients tolerated this study protocol. One patient developed a headache, and another patient had mild arterial hypoxemia during AM inhalation. None of them experienced other adverse effects, such as systemic hypotension, infection, or arrhythmia.

Plasma AM Level After Inhalation
Baseline plasma AM level in patients with idiopathic pulmonary arterial hypertension was significantly higher than the normal value, which was determined from pooled data of 15 age-matched healthy subjects (11.9±0.8 versus 9.3±0.1 fmol/mL, P<0.05). Inhalation of AM significantly increased the plasma AM level to 22.9±2.1 fmol/mL immediately after inhalation (Figure 1). The half-life of plasma AM after inhalation was approximately 20 minutes, and the elevation of AM lasted for >45 minutes. Plasma cAMP level increased significantly 30 minutes after the initiation of AM inhalation (10.8±0.7 to 12.0±0.6 pmol/mL, P<0.05), although plasma cGMP level was not significantly altered (6.5±1.0 to 6.8±1.0 pmol/mL, P=NS).

View larger version (15K): [in this window] [in a new window]   Figure 1. Changes in plasma AM level by inhalation of aerosolized AM in patients with idiopathic pulmonary arterial hypertension. Normal value indicates plasma AM level derived from 15 age-matched healthy subjects. Data are mean±SEM. *P<0.05 vs value at time 0.

Hemodynamic Effects of AM Inhalation
Inhalation of AM significantly decreased mean pulmonary arterial pressure in patients with idiopathic pulmonary arterial hypertension (54±3 to 47±3 mm Hg, P<0.05) without a significant decrease in mean arterial pressure (85±4 to 83±4 mm Hg, P=NS) (Figure 2). AM inhalation slightly but significantly increased cardiac index by 12% (2.4±0.1 to 2.7±0.2 L · min^-1 · m^-2, P<0.05). Thus, AM inhalation resulted in a 22% decrease in pulmonary vascular resistance (12.6±1.5 to 9.8±1.3 Wood units, P<0.05) (Figure 3). Inhaled AM did not significantly alter systemic vascular resistance. The ratio of pulmonary vascular resistance to systemic vascular resistance was decreased significantly at the end of inhalation (0.63±0.08 to 0.55±0.07, P<0.05). These hemodynamic effects of AM lasted for >45 minutes. No significant change in heart rate, pulmonary capillary wedge pressure, or right atrial pressure was observed. There was no significant change in arterial oxygen saturation (94±3% to 93±3%).

View larger version (17K): [in this window] [in a new window]   Figure 2. Changes in mean arterial pressure (MAP), mean pulmonary arterial pressure (MPAP), and cardiac index (CI) by inhalation of aerosolized AM in patients with idiopathic pulmonary arterial hypertension. Data are mean±SEM. *P<0.05 vs value at time 0.

View larger version (17K): [in this window] [in a new window]   Figure 3. Changes in pulmonary vascular resistance (PVR), systemic vascular resistance (SVR), and ratio of pulmonary vascular resistance to systemic vascular resistance (Rp/Rs) by inhalation of aerosolized AM in patients with idiopathic pulmonary arterial hypertension. Data are mean±SEM. *P<0.05 vs value at time 0.

Effects of AM Inhalation on Exercise Capacity and Ventilatory Efficiency
As the limiting symptom at the end of exercise, 6 patients reported muscle weakness and 4 reported dyspnea. There was no difference in these symptoms when exercise testing was performed with or without inhalation of AM. Inhalation of AM altered neither heart rate nor blood pressure either at rest or at peak exercise (Table 2). Inhalation of AM significantly increased peak workload (86±5 to 93±6 W, P<0.05) (Table 2). AM also significantly increased peak O₂ (14.6±0.6 to 15.7±0.6 mL · kg^-1 · min^-1, P<0.05) (Figure 4). Inhalation of AM significantly increased O₂/W ratio (6.3±0.4 to 7.0±0.5 mL · min^-1 · W^-1, P<0.05). AM did not significantly alter the E-CO₂ slope (Table 2). No significant changes in arterial oxygen saturation were observed either at rest or at peak exercise. In 1 patient with NYHA class IV who did not undergo cardiopulmonary exercise testing, the distance walked in 6 minutes increased from 150 to 180 m by inhalation of AM.

View this table: [in this window] [in a new window]   TABLE 2. Changes in Exercise Parameters by Inhalation of AM or Placebo

View larger version (19K): [in this window] [in a new window]   Figure 4. Changes in peak oxygen consumption (peak O2) and ratio of change in oxygen uptake to that in work rate (O2/W ratio) by inhalation of aerosolized AM or placebo in patients with idiopathic pulmonary arterial hypertension. Data are mean±SEM. *P<0.05 vs placebo.

	Discussion

Top Abstract Introduction Methods Results Discussion Conclusions References

 
In the present study, we demonstrated that inhalation of AM improved hemodynamics with pulmonary selectivity and exercise capacity in patients with idiopathic pulmonary arterial hypertension.

AM is one of the most potent endogenous vasodilators in the pulmonary vascular bed.^25–27 The vasodilatory effect is mediated by cAMP-dependent and nitric oxide–dependent mechanisms.^28,29 Endogenous AM production is enhanced in a variety of cardiovascular diseases through a compensatory mechanism.^14,30 Nonetheless, additional supplementation of AM has beneficial effects in these diseases.^18,19 These results suggest that endogenous AM level is not sufficient to improve deteriorated conditions despite the increased AM production. Interestingly, Champion et al³¹ have shown that intratracheal gene transfer of calcitonin gene–related peptide, a member of the same peptide family as AM, to bronchial epithelial cells attenuates chronic hypoxia-induced pulmonary hypertension in the mouse. These results raise the possibility that intratracheal delivery of a vasodilator peptide may be sufficient to alter pulmonary vascular function. In fact, in the present study, inhalation of AM significantly decreased pulmonary vascular resistance, whereas it did not alter systemic arterial pressure or systemic vascular resistance. The ratio of pulmonary vascular resistance to systemic vascular resistance was reduced significantly by AM inhalation. These results suggest that inhaled AM improves hemodynamics with pulmonary selectivity. This is consistent with earlier findings that inhaled prostacyclin or its analogue iloprost acts transepithelially with pulmonary selectivity and improves pulmonary hypertension.^20,21 Inhalation of AM slightly but significantly increased cardiac index in patients with idiopathic pulmonary arterial hypertension. Considering the strong vasodilator activity of AM in the pulmonary vasculature, the significant decrease in cardiac afterload may be responsible for increased cardiac index with AM. Interestingly, the hemodynamic effects of inhaled AM lasted for >45 minutes. A previous study demonstrated that intravenous injection of AM produces a long-lasting vasodilator response because of its long half-life (15 minutes).³² The half-life of plasma AM after inhalation was longer (20 minutes). Thus, inhalation of AM may cause relatively long-lasting pulmonary vasodilator activity in patients with idiopathic pulmonary arterial hypertension. In the present study, plasma cAMP level increased after AM inhalation, suggesting that the hemodynamic effects of AM may be mediated by activation of cAMP.

Earlier studies have shown that peak O₂ during exercise is markedly lower in patients with idiopathic pulmonary arterial hypertension than in healthy subjects.^33,34 Peak O₂ is determined primarily by the maximal cardiac output during exercise and the potential for O₂ extraction by the exercising muscle.³⁵ Thus, the decreased peak O₂ may reflect insufficient oxygen delivery to the body during exercise, at least in part because of an inadequate increase in cardiac output under conditions of severe pulmonary hypertension. In the present study, inhalation of AM significantly increased peak O₂ in patients with pulmonary hypertension. AM also increased the O₂/W ratio, which indicates oxygen transport per unit workload to the exercising legs. These results suggest that inhalation of AM improves exercise capacity in patients with idiopathic pulmonary arterial hypertension. It is possible that an increase in cardiac output during exercise may contribute to increases in peak O₂ and the O₂/W ratio.

The major limitation of this pilot trial relates to the lack of a randomized, placebo-controlled group in acute hemodynamic studies, which was as result not only of invasive assessment of hemodynamics but also of the limited number of patients available. Nevertheless, cardiopulmonary exercise testing was performed in a double-blind, randomized, crossover design. Thus, it is unlikely that the hemodynamic effects of inhaled AM are attributable to the placebo effect.

Inhalation therapy may be more simple, noninvasive, and comfortable than continuous intravenous infusion therapy. An experimental study demonstrated that repeated inhalation of AM (for 30 minutes, 4 times a day) inhibited monocrotaline-induced pulmonary hypertension and markedly improved survival in rats.³⁶ Recently, pulmonary delivery of a dry-powder insulin has been shown to improve glycemic control without adverse pulmonary effects.³⁷ Although further studies are necessary to maximize the efficiency and reproducibility of pulmonary AM delivery, combining AM inhalation therapy with other modalities that have a different mode of action may have beneficial effects in patients with idiopathic pulmonary arterial hypertension.

	Conclusions

Top Abstract Introduction Methods Results Discussion Conclusions References

 
These preliminary results suggest that inhalation of AM may have beneficial effects on pulmonary hemodynamics and exercise capacity in patients with idiopathic pulmonary arterial hypertension.

	Acknowledgments

 
This work was supported by grants from NEDO, the Mochida Memorial Foundation for Medical and Pharmaceutical Research, the Japan Cardiovascular Research Foundation, Health and Labor Sciences Research grant genome 005, and the Promotion of Fundamental Studies in Health Science of the Organization for Pharmaceutical Safety and Research of Japan. We thank Masahiko Shibakawa for preparing AM.

	References

Top Abstract Introduction Methods Results Discussion Conclusions References

 

1. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension: a national prospective study. Ann Intern Med. 1987; 107: 216–223.[CrossRef][Medline] [Order article via Infotrieve]
   
2. Rich S. Primary pulmonary hypertension. Prog Cardiovasc Dis. 1988; 31: 205–238.[CrossRef][Medline] [Order article via Infotrieve]
   
3. Rubin LJ, Peter RH. Oral hydralazine therapy for primary pulmonary hypertension. N Engl J Med. 1980; 302: 69–73.[Abstract]
   
4. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med. 1992; 327: 76–81.[Abstract]
   
5. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996; 334: 296–301.[Abstract/Free Full Text]
   
6. McLaughlin VV, Genthner DE, Panella MM, et al. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med. 1998; 338: 273–277.[Abstract/Free Full Text]
   
7. Nagaya N, Uematsu M, Okano Y, et al. Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension. J Am Coll Cardiol. 1999; 34: 1188–1192.[Abstract/Free Full Text]
   
8. Reitz BA, Wallwork JL, Hunt SA, et al. Heart-lung transplantation: successful therapy for patients with pulmonary vascular disease. N Engl J Med. 1982; 306: 557–564.[Abstract]
   
9. Pasque MK, Trulock EP, Kaiser LD, et al. Single lung transplantation for pulmonary hypertension: three month hemodynamic follow-up. Circulation. 1991; 84: 2275–2279.[Abstract/Free Full Text]
   
10. Kitamura K, Kangawa K, Kawamoto M, et al. Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun. 1993; 192: 553–560.[CrossRef][Medline] [Order article via Infotrieve]
    
11. Ichiki Y, Kitamura K, Kangawa K, et al. Distribution and characterization of immunoreactive adrenomedullin in human tissue and plasma. FEBS Lett. 1994; 338: 6–10.[CrossRef][Medline] [Order article via Infotrieve]
    
12. Sakata J, Shimokubo T, Kitamura K, et al. Distribution and characterization of immunoreactive rat adrenomedullin in tissue and plasma. FEBS Lett. 1994; 352: 105–108.[CrossRef][Medline] [Order article via Infotrieve]
    
13. Owji AA, Smith DM, Coppock HA, et al. An abundant and specific binding site for the novel vasodilator adrenomedullin in the rat. Endocrinology. 1995; 136: 2127–2134.[Abstract]
    
14. Kakishita M, Nishikimi T, Okano Y, et al. Increased plasma levels of adrenomedullin in patients with pulmonary hypertension. Clin Sci. 1999; 96: 33–39.[Medline] [Order article via Infotrieve]
    
15. Yoshibayashi M, Kamiya T, Kitamura K, et al. Plasma levels of adrenomedullin in primary and secondary pulmonary hypertension in patients < 20 years of age. Am J Cardiol. 1997; 79: 1556–1558.[CrossRef][Medline] [Order article via Infotrieve]
    
16. Horio T, Kohno M, Kano H, et al. Adrenomedullin as a novel antimigration factor of vascular smooth muscle cells. Circ Res. 1995; 77: 660–664.[Abstract/Free Full Text]
    
17. Kano H, Kohno M, Yasunari K, et al. Adrenomedullin as a novel antiproliferative factor of vascular smooth muscle cells. J Hypertens. 1996; 14: 209–213.[CrossRef][Medline] [Order article via Infotrieve]
    
18. Nagaya N, Satoh T, Nishikimi T, et al. Hemodynamic, renal, and hormonal effects of adrenomedullin infusion in patients with congestive heart failure. Circulation. 2000; 101: 498–503.[Abstract/Free Full Text]
    
19. Nagaya N, Nishikimi T, Uematsu M, et al. Haemodynamic and hormonal effects of adrenomedullin in patients with pulmonary hypertension. Heart. 2000; 84: 653–658.[Abstract/Free Full Text]
    
20. Walmrath D, Schneider T, Pilch J, et al. Aerosolized prostacyclin reduces pulmonary artery pressure and improves gas exchange in the adult respiratory distress syndrome (ARDS). Lancet. 1993; 342: 961–962.[CrossRef][Medline] [Order article via Infotrieve]
    
21. Hoeper MM, Schwarze M, Ehlerding S, et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med. 2000; 342: 1866–1870.[Abstract/Free Full Text]
    
22. Rich S, Seidlitz M, Dodin E, et al. The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension. Chest. 1998; 114: 787–792.[Abstract/Free Full Text]
    
23. Miyamoto S, Nagaya N, Satoh T, et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension: comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med. 2000; 161: 487–492.[Abstract/Free Full Text]
    
24. Ohta H, Tsuji T, Asai S, et al. A simple immunoradiometric assay for measuring the entire molecules of adrenomedullin in human plasma. Clin Chim Acta. 1999; 287: 131–143.[CrossRef][Medline] [Order article via Infotrieve]
    
25. Lippton H, Chang JK, Hao Q, et al. Adrenomedullin dilates the pulmonary vascular bed in vivo. J Appl Physiol. 1994; 76: 2154–2156.[Abstract/Free Full Text]
    
26. Heaton J, Lin B, Chang JK, et al. Pulmonary vasodilation to adrenomedullin: a novel peptide in humans. Am J Physiol. 1995; 268: H2211–H2215.[Medline] [Order article via Infotrieve]
    
27. Nossaman BD, Feng CJ, Kaye AD, et al. Pulmonary vasodilator responses to adrenomedullin are reduced by NOS inhibitors in rats but not in cats. Am J Physiol. 1996; 270: L782–L789.[Medline] [Order article via Infotrieve]
    
28. Ishizaka Y, Ishizaka Y, Tanaka M, et al. Adrenomedullin stimulates cyclic AMP formation in rat vascular smooth muscle cells. Biochem Biophys Res Commun. 1994; 200: 642–646.[CrossRef][Medline] [Order article via Infotrieve]
    
29. Nakamura M, Yoshida H, Makita S, et al. Potent and long-lasting vasodilatory effects of adrenomedullin in humans: comparisons between normal subjects and patients with chronic heart failure. Circulation. 1997; 95: 1214–1221.[Abstract/Free Full Text]
    
30. Nagaya N, Nishikimi T, Yoshihara F, et al. Cardiac adrenomedullin gene expression and peptide accumulation after acute myocardial infarction in rats. Am J Physiol. 2000; 278: R1019–R1026.
    
31. Champion HC, Bivalacqua TJ, Toyoda K, et al. In vivo gene transfer of prepro-calcitonin gene-related peptide to the lung attenuates chronic hypoxia-induced pulmonary hypertension in the mouse. Circulation. 2000; 101: 931–937.[Abstract/Free Full Text]
    
32. Ishiyama Y, Kitamura K, Ichiki Y, et al. Haemodynamic responses to rat adrenomedullin in anaesthetized spontaneously hypertensive rats. Clin Exp Pharmacol Physiol. 1995; 22: 614–618.[Medline] [Order article via Infotrieve]
    
33. D’Alonzo GE, Gianotti LA, Pohil RL, et al. Comparison of progressive exercise performance of normal subjects and patients with primary pulmonary hypertension. Chest. 1987; 92: 57–62.[Abstract/Free Full Text]
    
34. Wensel R, Opitz CF, Anker SD, et al. Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing. Circulation. 2002; 106: 319–324.[Abstract/Free Full Text]
    
35. Anderson P, Saltin B. Maximal perfusion of skeletal muscle in man. J Appl Physiol. 1985; 366: 233–249.
    
36. Nagaya N, Okumura H, Uematsu M, et al. Repeated inhalation of adrenomedullin ameliorates pulmonary hypertension and survival in monocrotaline rats. Am J Physiol Heart Circ Physiol. 2003; 285: H2125–H2131.[Abstract/Free Full Text]
    
37. Skyler JS, Cefalu WT, Kourides IA, et al. Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomised proof-of-concept study. Lancet. 2001; 357: 331–335.[CrossRef][Medline] [Order article via Infotrieve]
    

This article has been cited by other articles:

				A. Geambasu and T. L. Krukoff Adrenomedullin acts in the lateral parabrachial nucleus to increase arterial blood pressure through mechanisms mediated by glutamate and nitric oxide Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2008; 295(1): R38 - R44. [Abstract] [Full Text] [PDF]

				C. Ertmer, A. Morelli, S. Rehberg, M. Lange, C. Hucklenbruch, H. Van Aken, M. Booke, and M. Westphal Exogenous adrenomedullin prevents and reverses hypodynamic circulation and pulmonary hypertension in ovine endotoxaemia Br. J. Anaesth., December 1, 2007; 99(6): 830 - 836. [Abstract] [Full Text] [PDF]

				T. Itoh, H. Obata, S. Murakami, K. Hamada, K. Kangawa, H. Kimura, and N. Nagaya Adrenomedullin ameliorates lipopolysaccharide-induced acute lung injury in rats Am J Physiol Lung Cell Mol Physiol, August 1, 2007; 293(2): L446 - L452. [Abstract] [Full Text] [PDF]

				S. I. Said Mediators and modulators of pulmonary arterial hypertension Am J Physiol Lung Cell Mol Physiol, October 1, 2006; 291(4): L547 - L558. [Abstract] [Full Text] [PDF]

				J. Kato, T. Tsuruda, T. Kita, K. Kitamura, and T. Eto Adrenomedullin: A Protective Factor for Blood Vessels Arterioscler. Thromb. Vasc. Biol., December 1, 2005; 25(12): 2480 - 2487. [Abstract] [Full Text] [PDF]

				S. Provencher, X. Jais, A. Yaici, O. Sitbon, M. Humbert, and G. Simonneau Clinical Challenges in Pulmonary Hypertension: Roger S. Mitchell Lecture Chest, December 1, 2005; 128(6_suppl): 622S - 628S. [Abstract] [Full Text] [PDF]

				N. Nagaya, H. Mori, S. Murakami, K. Kangawa, and S. Kitamura Adrenomedullin: angiogenesis and gene therapy Am J Physiol Regulatory Integrative Comp Physiol, June 1, 2005; 288(6): R1432 - R1437. [Abstract] [Full Text] [PDF]

				T. Nagaoka, K. A. Fagan, S. A. Gebb, K. G. Morris, T. Suzuki, H. Shimokawa, I. F. McMurtry, and M. Oka Inhaled Rho Kinase Inhibitors Are Potent and Selective Vasodilators in Rat Pulmonary Hypertension Am. J. Respir. Crit. Care Med., March 1, 2005; 171(5): 494 - 499. [Abstract] [Full Text] [PDF]

				T. Fujii, N. Nagaya, T. Iwase, S. Murakami, Y. Miyahara, K. Nishigami, H. Ishibashi-Ueda, M. Shirai, T. Itoh, K. Ishino, et al. Adrenomedullin enhances therapeutic potency of bone marrow transplantation for myocardial infarction in rats Am J Physiol Heart Circ Physiol, March 1, 2005; 288(3): H1444 - H1450. [Abstract] [Full Text] [PDF]

				S. M. Lowson Alternatives to nitric oxide Br. Med. Bull., November 5, 2004; 70(1): 119 - 131. [Abstract] [Full Text] [PDF]

				M. Westphal, M. Booke, and A.T. Dinh-Xuan Adrenomedullin: a smart road from pheochromocytoma to treatment of pulmonary hypertension Eur. Respir. J., October 1, 2004; 24(4): 518 - 520. [Full Text] [PDF]

				D. J. Stewart, Y. D. Zhao, D. W. Courtman, N. Nagaya, T. Horio, K. Miyatake, Y. Chiba, K. Kangawa, M. Kanda, J. Hino, et al. Cell Therapy for Pulmonary Hypertension: What Is the True Potential of Endothelial Progenitor Cells? * Response Circulation, March 30, 2004; 109(12): e172 - e173. [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: 109/3/351    most recent 01.CIR.0000109493.05849.14v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nagaya, N. Articles by Kangawa, K. Search for Related Content PubMed PubMed Citation Articles by Nagaya, N. Articles by Kangawa, K. Related Collections Pulmonary circulation and disease